Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children
3상
완료
NCT04816643
| 대상 질환 | SARS-CoV-2 Infection, COVID-19 |
|---|
| 임상 단계 | 3상 |
|---|
| 스폰서 | BioNTech SE |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 11,837 명 |
|---|
| 중재(약물) | Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg, Biological/Vaccine: BNT162b2 3mcg |
|---|
| 시작일 | 2021년 3월 24일 |
|---|
| 완료일 | 2023년 10월 4일 |
|---|
| 결과 공개일 | 2026년 5월 28일 |
|---|
요약
This is a Phase 1/2/3 study in healthy children. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants \<6 months of age may subsequently be evaluated.
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age
Phase 1: From Day 1 to Day 7 after Dose 1 · Percentage of participants
| Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | 12.5 Percentage of participants |
|---|
| Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | 0 Percentage of participants |
|---|
| Phase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of Age | 100.0 Percentage of participants |
|---|
| Phase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age | 16.7 Percentage of participants |
|---|
| Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | 6.3 Percentage of participants |
|---|
| Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | 0 Percentage of participants |
|---|
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age
Phase 1: Day 1 to Day 7 after Dose 2 · Percentage of participants
| Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | 37.5 Percentage of participants |
|---|
| Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | 18.8 Percentage of participants |
|---|
| Phase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of Age | 75.0 Percentage of participants |
|---|
| Phase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age | 16.7 Percentage of participants |
|---|
| Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age | 25.0 Percentage of participants |
|---|
| Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age | 6.3 Percentage of participants |
|---|
Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age
Phase 1: Day 1 to Day 7 after Dose 3 · Percentage of participants
| Phase 1: 5 to <12 Years BNT162b2 10 mcg | 28.9 Percentage of participants |
|---|
| Phase 1: 5 to <12 Years BNT162b2 10 mcg | 21.1 Percentage of participants |
|---|
| Phase 1: 5 to <12 Years BNT162b2 10 mcg | 7.9 Percentage of participants |
|---|
| Phase 1: 5 to <12 Years BNT162b2 10 mcg | 0 Percentage of participants |
|---|
| Phase 1: 5 to <12 Years BNT162b2 10 mcg | 0 Percentage of participants |
|---|
| Phase 1: 5 to <12 Years BNT162b2 10 mcg | 13.2 Percentage of participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.